DTUK1710

June 28-July 4, 201014 perio Tribune United Kingdom Edition LADDEC® SPMP08263 REV A NOV 2008 BioHorizons UK is proud to announce the exclusive distribution of LADDEC • Biocompatible mineralized matrix with structure and composition similar to that of autogenous bone graft material. • Facilitates osteogenesis through the process of bone remodelling. • Processing ensures preservation of the natural mineral and collagen framework. • Available in multiple forms including Particulate (Jar or Syringe), Cube and Block. Dental Bone Graft Similar characteristics to autogenous bone For more information about LADDEC, please call us on +44(0)1344 752560 or email infouk@biohorizons.com or visit www.biohorizons.com SPMP08263 LADDEC Ad UK A4.indd 1 2/23/2009 8:52:29 AM periodontology is innovative prof. Dr. Liviu Steier looks at some of the new ideas in periodontology as discussed by Robert J Genco G enco summarised in his paper published the Journal of Periodontol- ogy the, ‘clinical implications of the workshop on inflammation and periodontal diseases’. In this paper, he managed to compile a list of innovations currently still in the pip-line. These can be cat- egorised as follows: Short-term: ready for clinical application over the next one to two years; Mid-term: ready for clinical application over the next five to 10 years; Long-term: ready for clinical application more than 10 years from today New risk profiles under development for periodontal disease and diabetes to be self- reported used in practice. Risk assessment of risk for potential atherothrombotic vas- cular events in dental patients, with special consideration for those having periodontal disease using traditional markers of risk or C-reactive protein (CRP) in the Reynolds Risk Score. New strategies for manage- ment of periodontal disease in patients suffering of diabetes and cardiovascular disease. Indication for use of nutraceu- tical and drug combinations (ome- ga-3 fatty acid and aspirin) to con- trol inflammation associated with periodontal infections. Indication and application for use of inhibitors of matrix metal- loproteinase for adjunctive man- agement of periodontal disease as an adjuvant in surgical and non-surgical therapy. Mid-term innovations 1) New diagnosis technology for measuring active bone loss 2) Application of diet diet rich in omega-3 fatty acids to reduce genetic predilection to metabolic syndrome and the application of nutragenomics 3) Therapeutic approach to use of anti-inflammatory agents, the endogenous resolvins and protectins 4) New tests to control MMP-8 in saliva, and fragments of bone collagen in tissue fluids for monitoring periodontal disease 5) The application of bone spar- ing agents to inhibit osteoclast recruitment and limit bone loss 6) Application of statins and targeted anti-inflammatory therapies in periodontal disease for modulation of inflammation Long-term innovations 1) New approaches to regulate and prevent bone loss 2) Apoptosis regulation to re- duce bone loss 3) Dietary modulation with genetic influence on phenotype in pathogenic pathways, for example, cholesterol levels and obesity – leading to prevention and treatment of cardiovascu- lar diseases and other complex inflammatory disease such as periodontal disease 4) Identification of genetic risk profiles for periodontal disease 5) Genetic test to identify cor- relation between CRP, inflam- matory mediators, periodontal disease, diabetes, and premature atherothrombosis 6) New data and information regarding pathogenesis of peri- odontal disease which may be modeled by incorporating gene, protein, and metabolite into dynamic biologic networks 7) Vaccines using periodontal pathogens to protect against periodontal infection 8) New prevention approaches to avoid uncoupling of bone deposition and bone resorption. DT Reference Robert J Genco, Clinical Innovations in Managing Inflammation and Periodontal Diseases: The Workshop on Inflammation and Periodontal Diseases; Journal of Periodontology, August 2008, Vol. 79, No. 8s, Pages 1609-1611